Yüklüyor......
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
OBJECTIVE: To determine the safety and clinical efficacy of two anti-angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone. PATIENTS AND METHODS: Eligible patients with metastatic castration-resistant prostate cancer enrolled in this open-label, phase II study of lenalidomid...
Kaydedildi:
| Yayımlandı: | BJU Int |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6387685/ https://ncbi.nlm.nih.gov/pubmed/26780387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.13412 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|